Regresar

Microbiota and probiotics in inflammatory bowel disease and irritable bowel syndrome

Abstract:

Background: Chronic intestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) in its entities the ulcerative colitis (UC) and the Crohn's disease (CD) are characterized for presenting a multifactorial etiopathogenesis in which two points stand out: the altered inmune response of the enteric microbiota and its dysregulation known as intestinal dysbiosis. For this reason, in the last few years the use of probiotics has been studied as a coadjuvant therapy for this pathologies and the objective of this narrative review is to describe the evidence associated with the use of probiotics in the management of these gastrointestinal pathologies. Methods: A systematic research was performed in the following databases: PubMed®, Trip®, Scopus® y Google Scholar® using the meSH terms: "probiotics", "gut", "microbiota", " microbiome", "inflammatory bowel disease", "irritable bowel syndrome", "Crohn's disease" and "ulcerative colitis" . Results: Managing to identify 93 articles evaluated in relevance and pertinence obtaining a total of 58 articles. Conclusions: In the management of IBS and UC the use of probiotics present a benefit in the remission of symptoms, different from CD where there isn't a clear benefit in relation to the effect of probiotics.